Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for gene therapy delandistrogene moxeparvovec, for the treatment of Duchenne muscular dystrophy (DMD).
Trade-marked Elevidys overseas, the drug’s target population aims to include ambulatory boys aged three-seven years with DMD who do not have any deletion in exons 8 and/or 9 in the DMD gene and do not have a pre-existing immunity against AAVrh74, said Chugai, which licensed the drug from its majority owner Swiss pharma giant Roche (ROG: SIX) in 2021.
Marketresearch.biz has previously reported that the Duchenne muscular dystrophy market was valued at $3.5 billion in 2023. It is expected to reach $11.7 billion in 2033, with a compound annual growth rate (CAGR) of 13.16% during the forecast period from 2024 to 2033.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze